This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wilson, J. W. Articles by Potten, C. S. Search for Related Content PubMed PubMed Citation Articles by Wilson, J. W. Articles by Potten, C. S.

The Effect of Exogenous Prostaglandin Administration on Tumor Size and Yield in Min/+ Mice¹

Cancer Research Campaign Epithelial Biology Laboratory, Section of Cell and Tumour Biology, Paterson Institute for Cancer Research, Manchester M20 4BX, United Kingdom

This study set out to examine the effect of exogenous prostaglandin (PG) administration on tumor development in Min/+ mice. Mice were treated with the stable prostaglandin E₂ analogue 16,16-dimethyl-PGE₂ from 6–18 weeks of age. Mice were sacrificed, and tumor burden was assessed using morphometric techniques. Parameters measured were median tumor size, mean tumor size, the proportion of the area of the gastrointestinal mucosa covered with tumor, and the number of tumors per 1000 mm² of gastrointestinal mucosa. In addition, proliferative and apoptotic indices were determined. These measurements were carried out for all regions of the small intestine (i.e., duodenum, jejunum, upper ileum, and lower ileum) and the large intestine (i.e., cecum and mid-colon/rectum). 16,16-Dimethyl-PGE₂-treated animals showed a significant decrease in tumor burden (by approximately 50–70%), in comparison with those animals that were treated with vehicle alone (0.001% ethanol in 0.9% sterile saline), in all regions of the intestine (at P = 0.008 or better). This effect was contributed to by a reduction in the number of tumors (by approximately 20–50%) and a reduction in tumor size (by approximately 10–70%). An increase in tumor cell turnover was associated with this decrease in tumor burden, as determined by the changes in the levels of thymidine incorporation (significant at P = 0.003), apoptosis, and mitosis (nonsignificant).

This article has been cited by other articles:

				M. A Frias, S. Somers, C. Gerber-Wicht, L. H Opie, S. Lecour, and U. Lang The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis Cardiovasc Res, July 9, 2008; (2008) cvn171v2. [Abstract] [Full Text] [PDF]

				P. Khalili, A. Arakelian, G. Chen, M. L. Plunkett, I. Beck, G. C. Parry, F. Donate, D. E. Shaw, A. P. Mazar, and S. A. Rabbani A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther., September 1, 2006; 5(9): 2271 - 2280. [Abstract] [Full Text] [PDF]

				J. P. Meng, S. Ceryak, Z. Aratsu, L. Jones, L. Epstein, and B. Bouscarel Biphasic regulation by bile acids of dermal fibroblast proliferation through regulation of cAMP production and COX-2 expression level Am J Physiol Cell Physiol, September 1, 2006; 291(3): C546 - C554. [Abstract] [Full Text] [PDF]

				M. A. Hull, S. C.W. Ko, and G. Hawcroft Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol. Cancer Ther., August 1, 2004; 3(8): 1031 - 1039. [Abstract] [Full Text] [PDF]

				A. Pozzi, X. Yan, I. Macias-Perez, S. Wei, A. N. Hata, R. M. Breyer, J. D. Morrow, and J. H. Capdevila Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation J. Biol. Chem., July 9, 2004; 279(28): 29797 - 29804. [Abstract] [Full Text] [PDF]

				T. Kawamori, N. Uchiya, T. Sugimura, and K. Wakabayashi Enhancement of colon carcinogenesis by prostaglandin E2 administration Carcinogenesis, May 1, 2003; 24(5): 985 - 990. [Abstract] [Full Text] [PDF]

				D. K. Bol, R. B. Rowley, C.-P. Ho, B. Pilz, J. Dell, M. Swerdel, K. Kiguchi, S. Muga, R. Klein, and S. M. Fischer Cyclooxygenase-2 Overexpression in the Skin of Transgenic Mice Results in Suppression of Tumor Development Cancer Res., May 1, 2002; 62(9): 2516 - 2521. [Abstract] [Full Text] [PDF]

				M. B. Hansen-Petrik, M. F. McEntee, B. Jull, H. Shi, M. B. Zemel, and J. Whelan Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice Cancer Res., January 1, 2002; 62(2): 403 - 408. [Abstract] [Full Text] [PDF]